7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2013-12-31 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 
      
    		                                                                           
      cash flows from operating activities
    		                                                                           
      net income
    		26,617,000 8,549,000 15,681,000 -10,276,000 -24,166,000 -2,287,000 18,207,000 1,155,000 9,940,000 6,245,000 1,439,000 -4,243,000 -8,600,000    -4,447,000        3,895,000 6,585,000 449,000  5,037,000 2,777,000 2,250,000  4,720,000 2,681,000 1,152,000 -1,080,000 2,543,000 1,125,000 1,346,000 2,876,000 4,559,000 3,571,000 4,369,000    -2,290,649 -3,987,331 -6,121,815 -7,344,116 -10,264,477 -6,648,905 -12,733,692 -14,975,231 -17,250,676 -13,271,735 -11,589,711 -10,794,351 -10,540,419 -32,485,898 -6,370,557 -4,620,701 -4,050,612 -1,165,389 -6,585,084 -6,048,067 -3,626,638 -1,674,064 -1,693,044 -2,400,309 -1,817,018 8,989,729    
      adjustments to reconcile net income to net cash from operating activities:
    		                                                                           
      stock-based compensation
    		9,691,000 9,602,000 8,868,000 7,061,000 7,485,000 7,864,000 6,934,000 5,621,000 5,444,000 5,249,000 4,338,000 3,737,000 3,869,000 3,756,000 3,237,000 2,968,000 2,808,000 2,844,000 1,869,000 2,393,000 2,383,000 5,736,000 2,424,000 2,444,000 2,470,000 2,593,000 1,710,000 1,828,000 1,795,000 1,782,000 1,377,000 1,422,000 1,475,000 1,807,000 1,386,000 1,380,000 1,365,000 2,217,000 1,105,000 1,139,000 1,120,000 1,029,000 568,000 704,000 693,000 33,049                              
      deferred taxes
    		18,800,000 -3,536,000 -3,383,000 -17,530,000 -5,588,000 -1,899,000 3,104,000 -8,346,000 -3,257,000 -910,000 773,000 -1,625,000 -2,250,000 -3,914,000 -7,464,000 -8,089,000 -1,989,000 -6,397,000 -279,000 -4,173,000 5,068,000 5,143,000 -19,243,000 -2,701,000 -3,728,000 -2,540,000 -165,000 -2,599,000 -1,594,000 -491,000 -496,000 8,162,000 -2,896,000 -971,000 -735,000 -7,827,000 -649,000 -354,000 -81,000 -1,932,000 -358,000 119,000 294,000                                 
      depreciation and amortization
    		22,632,000 23,281,000 22,891,000 22,600,000 15,748,000 14,697,000 14,686,000 15,194,000 15,207,000 14,690,000 14,700,000 15,572,000 15,350,000 14,174,000 14,557,000 13,684,000 11,346,000 11,324,000 10,898,000 10,899,000 11,358,000 11,198,000 11,183,000 9,564,000 9,473,000 9,472,000 16,103,000 8,686,000 8,548,000 8,313,000 8,195,000 7,022,000 7,099,000 7,101,000 6,706,000 5,812,000 5,966,000 5,956,000 4,609,000 2,111,000 2,047,000 1,415,000 1,327,000 1,282,000 1,187,000 437,172 166,386 171,398 25,749 30,933 30,866 30,108 35,669 40,519 41,944 39,019 41,000 42,546 45,421 41,393 33,308 33,333 29,246 9,296 11,759 12,309 9,773 10,315 17,993 28,600 32,916 32,490 30,725 27,109 27,457 
      unrealized gain on investment in equity securities
    		-3,140,000 -332,000 921,000 1,991,000 -1,355,000 2,712,000 -9,655,000                                                                     
      non-cash operating lease expense
    		358,000 394,000 452,000 392,000 384,000 377,000 373,000 381,000 827,000                                                                   
      non-cash interest
    		340,000 341,000 324,000 323,000 121,000 96,000 102,000 952,000 997,000 986,000 987,000 998,000 994,000 987,000 982,000 794,000 577,000 569,000 572,000 588,000                                                        
      contingent consideration fair value adjustment
    		-14,470,000 1,277,000 -12,092,000 -1,893,000 825,000 359,000 90,000 1,985,000 -2,555,000 1,035,000 961,000 1,924,000 2,476,000 -1,095,000 753,000                                                             
      gain on disposal of assets
    		                                                                           
      loss on debt extinguishment
    		                                                                           
      amortization of inventory step up
    		   10,375,000                                                                        
      asset impairment charges
    		           0 -1,000                                                               
      changes in operating assets and liabilities:
    		                                                                           
      accounts receivable
    		-26,965,000 -5,491,000 1,782,000 -25,513,000 8,438,000 6,327,000 -10,339,000 16,763,000 -5,918,000 1,789,000 -9,275,000 -25,005,000 9,977,000 -18,785,000 -3,099,000 5,373,000 -14,066,000 -772,000 3,917,000 -12,048,000 -10,583,000 9,217,000 -10,250,000 -1,429,000 5,574,000 -8,864,000 -2,568,000 2,805,000 -10,221,000 -1,314,000 3,987,000 3,386,000 -6,661,000 -8,816,000 -802,000 1,582,000 -11,915,000 -13,081,000 -549,000 -287,000 -2,765,000 -1,509,000 -74,000 -2,727,000 -6,776,000 -2,998,305          0 53,156   94,334 79,062     8,926 -15,652 3,567,726 -4,953 -62,628 6,995,818     
      inventories
    		-8,160,000 -908,000 -625,000 -675,000 -6,360,000 -11,611,000 -2,641,000 -4,605,000 -2,268,000 -669,000 1,701,000 -9,462,000 -3,312,000 -9,390,000 -1,462,000 -5,549,000 5,950,000 1,947,000 876,000 -1,608,000 -5,206,000 362,000 3,693,000 -1,989,000 -878,000 -3,264,000 -1,529,000 -497,000 -53,000 -3,262,000 3,433,000 751,000 3,829,000 3,586,000 -2,810,000 2,078,000 -3,209,000 -272,000 -535,000 354,000 -1,040,000 -1,964,000 -3,219,000 -172,000 -902,000 -708,525                              
      prepaid expenses and other assets
    		-6,454,000 9,835,000 -3,945,000 -1,693,000 2,045,000                                          100,928    84,227    1,332,339    455,862       -341,174 -532,297         
      accounts payable
    		13,766,000 3,076,000 5,549,000 -6,821,000 -3,079,000 -1,147,000 11,526,000 2,780,000 5,572,000 -3,905,000 3,105,000 10,065,000 -9,074,000 5,056,000 -1,009,000 9,770,000 -1,292,000 -774,000 2,462,000 -2,148,000 -811,000 1,997,000 -1,332,000 2,909,000 798,000 -673,000 2,005,000 1,216,000 -2,321,000 2,866,000 1,705,000 -2,075,000 2,423,000 -1,663,000 1,318,000 -1,486,000 -288,000 1,961,000 889,000 -897,000 1,249,000 -908,000 -471,000 -405,000 328,000 -658,280                              
      accrued royalties
    		15,217,000 12,317,000 1,087,000 -821,000 3,090,000 4,882,000 -801,000 9,637,000 -2,091,000 -227,000 -350,000 2,722,000 290,000 1,297,000 -1,227,000 2,144,000 -692,000 -622,000 -1,097,000 319,000 84,000 -281,000 1,201,000 -443,000 -738,000 825,000 -3,016,000 1,001,000 -764,000 -3,142,000 -803,000 423,000 -139,000 1,549,000 -2,250,000 187,000 3,659,000                                       
      income taxes
    		-12,548,000                                                                           
      accrued government rebates
    		4,166,000 10,222,000 3,930,000 7,635,000 -1,631,000 2,814,000 -2,658,000 1,347,000 1,048,000 1,166,000 -2,265,000 2,127,000 -695,000 4,883,000 -935,000 -6,965,000 2,973,000 68,000 846,000 -3,852,000 1,961,000 1,687,000 -871,000 -283,000 -1,759,000 2,391,000 -422,000 -40,000 3,758,000 -1,215,000 -1,459,000 2,175,000 2,221,000 -1,121,000 -1,236,000                                         
      returned goods reserve
    		1,322,000 6,220,000 3,189,000 4,806,000 77,000 1,045,000 3,174,000 -1,761,000 1,640,000 -4,314,000 713,000 -581,000 -915,000 -655,000 -248,000 1,412,000 337,000 2,962,000 1,792,000 3,913,000 3,048,000 2,389,000 1,019,000 650,000 1,289,000 1,097,000 1,007,000 1,712,000 1,076,000 744,000 746,000 -43,000 759,000 1,782,000 20,000                                         
      accrued expenses, accrued compensation, and other
    		1,821,000 11,859,000 -17,077,000 5,446,000 8,985,000 7,030,000 -13,077,000 4,451,000 4,981,000 -153,000 2,992,000 2,835,000 -4,926,000 5,631,000 -4,445,000 -4,170,000 -6,471,000 8,409,000 -1,406,000 278,000 111,000 2,332,000 -365,000 -826,000 2,241,000 -1,046,000 55,000                                                 
      net cash from operating activities
    		44,055,000 75,812,000 34,991,000 15,860,000 12,474,000 17,414,000 18,269,000 44,740,000 32,169,000 20,626,000 21,424,000     -12,185,000 -5,402,000 241,000 20,668,000 -5,709,000 -1,614,000 20,880,000 1,710,000 4,803,000 21,793,000 4,744,000 14,291,000 27,232,000 8,319,000 8,593,000 22,930,000 15,805,000 17,084,000 1,000 6,529,000 12,082,000 1,084,000 3,337,000 10,969,000  10,236,000 1,206,000 1,120,000                       -4,684,434 -2,460,126   -2,039,260 3,555,216     
      capex
    		-6,103,000 -4,014,000 -2,474,000 -2,394,000 -4,812,000 -4,449,000 -4,581,000 -2,279,000 -1,739,000 -2,501,000 -2,349,000     -356,000 -571,000 -932,000 -698,000 -2,110,000 -1,761,000 -725,000 -1,539,000 -1,703,000 -1,523,000 -1,634,000 -1,775,000 -1,007,000 -1,372,000 -1,086,000 -2,278,000 -3,447,000 -2,480,000 -2,304,000 -2,138,000 -1,389,000 -1,089,000 -719,000 -1,369,000  -768,000 -198,000 -112,000                       0 0   0 0     
      free cash flows
    		37,952,000 71,798,000 32,517,000 13,466,000 7,662,000 12,965,000 13,688,000 42,461,000 30,430,000 18,125,000 19,075,000     -12,541,000 -5,973,000 -691,000 19,970,000 -7,819,000 -3,375,000 20,155,000 171,000 3,100,000 20,270,000 3,110,000 12,516,000 26,225,000 6,947,000 7,507,000 20,652,000 12,358,000 14,604,000 -2,303,000 4,391,000 10,693,000 -5,000 2,618,000 9,600,000  9,468,000 1,008,000 1,008,000                       -4,684,434 -2,460,126   -2,039,260 3,555,216     
      cash flows from investing activities
    		                                                                           
      acquisition of alimera, net of cash acquired
    		   -8,201,000                                                                        
      acquisition of product rights, intangible assets, and other related assets
    		-60,000 -2,895,000 -17,372,000 -86,000                                                                        
      acquisition of property and equipment
    		-6,103,000 -4,014,000 -2,474,000 -2,394,000 -4,812,000 -4,449,000 -4,581,000 -2,279,000 -1,739,000 -2,501,000 -2,349,000 -3,138,000 -2,468,000 -1,321,000 -1,949,000 -356,000 -571,000 -932,000 -698,000 -2,110,000 -1,761,000 -725,000 -1,539,000 -1,703,000 -1,523,000 -1,634,000 -1,775,000 -1,007,000 -1,372,000 -1,086,000 -2,278,000 -3,447,000 -2,480,000 -2,304,000 -2,138,000 -1,389,000 -1,089,000 -719,000 -1,369,000 -1,105,000 -768,000 -198,000 -112,000 -338,000 -411,000                               
      proceeds from the sale of building
    		   0 0 0 13,514,000                                                                     
      net cash from investing activities
    		-6,163,000 -6,909,000 -19,846,000 -10,681,000 -398,522,000 -4,449,000 8,933,000 -4,779,000 -4,553,000 -6,826,000 -2,353,000 -3,142,000 -9,814,000 -604,000 -2,178,000 -82,213,000 -583,000 -21,950,000 -737,000 -2,119,000 -5,809,000 -2,848,000 -57,546,000 -1,374,000 -1,932,000 -3,958,000 -20,285,000 -407,000 -18,439,000 -6,255,000 -2,278,000 -50,115,000 -2,480,000 -2,304,000 -53,094,000 -1,390,000 -1,089,000 -66,032,000 -85,551,000  -26,768,000 -198,000 -4,612,000                 -12,309 -741 0 2,873,660 8,578,479 962,828 1,869,918 -82,699   -53,757 -60,988 6,107,779 -5,567,479 2,609,597 1,805,759 
      cash flows from financing activities
    		                                                                           
      proceeds from convertible notes
    		   0                                                                        
      proceeds from term loan
    		   0                                                                        
      purchase of capped call transaction
    		   0                                                                        
      repayment on borrowings under credit agreement
    		   0                                                                        
      debt issuance costs
    		   -1,977,000                                                                        
      principal payments on borrowings
    		-2,031,000                                                                           
      series a convertible preferred stock dividends paid
    		-344,000 -407,000 -406,000 -406,000 -406,000 -407,000 -406,000 -406,000 -406,000 -407,000 -406,000 -407,000 -406,000 -407,000 -405,000                                                             
      proceeds from stock option exercises and espp purchases
    		9,790,000 1,242,000 2,534,000 1,700,000 1,192,000 1,005,000 2,591,000 1,969,000 5,581,000 1,289,000 157,000 768,000 484,000 203,000 3,000 1,733,000 0   169,000 0                                                       
      treasury stock purchases for restricted stock vests
    		-1,044,000 -551,000 -10,003,000 -318,000 -680,000 -1,300,000 -8,661,000 -231,000 -670,000 -537,000 -3,549,000 -119,000 -239,000 -483,000 -1,118,000 -1,000 -73,000 -468,000 -348,000 0 0 -1,035,000 -488,000                                                     
      payments on contingent consideration
    		   0 0 0 -12,500,000                                                                     
      payment of accrued licensor payments
    		                                                                           
      net cash from financing activities
    		6,345,000 -1,747,000 -9,906,000 -4,907,000 291,030,000 -1,452,000 -19,726,000 -11,918,000 3,755,000 80,150,000 -4,548,000      -3,022,000    -2,378,000 -10,744,000 13,891,000  -770,000 1,580,000 1,206,000  -731,000 691,000 170,000          714,000 160,000 18,000     -7,933    -1,375,448 45,160,113 -13,281 23,888,627 16,865,766 -264 14,115,849 17,473,307 22,838,146    -60,343 345,750   24,736 142,690 18,184,443 142,662 -1 7,146,937 -6,323 243,675 
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		576,000 841,000 -297,000 -395,000                                                                        
      net change in cash, cash equivalents, and restricted cash
    		44,813,000 67,997,000 4,942,000 -123,000 -95,093,000 11,513,000 7,476,000  31,371,000 93,950,000 14,523,000                                                                 
      cash, cash equivalents, and restricted cash, beginning of period
    		0 0 144,894,000  0 0 221,121,000  0 0 53,234,000 0 0 0 105,301,000 0 0 0 12,867,000 0 0 0 67,361,000 0 0 0 48,029,000 0 0 0 36,150,000 0 0 0 32,367,000                                         
      cash, cash equivalents, and restricted cash end of period
    		44,813,000 67,997,000 149,836,000                                                                         
      gain on sale of building
    		   0 0 0 -5,347,000                                                                     
      supplemental disclosure for cash flow information:
    		                                                                           
      cash paid for interest, net of amounts capitalized
    		 4,966,000 8,895,000   8,209,000 7,946,000    4,293,000 7,449,000 2,628,000 5,763,000 5,637,000 3,783,000 1,969,000 1,970,000 1,983,000 1,851,000 1,539,000 1,693,000 1,848,000 2,465,000 690,000 2,488,000 449,000 2,522,000 584,000 2,726,000 453,000 1,562,000 100,000                                           
      cash paid for income taxes
    		 16,188,000 285,000   16,352,000 852,000    2,741,000 132,000 32,000   2,011,000 0 8,248,000 112,000 106,000 4,355,000 428,000 95,000 140,000 1,170,000   2,507,000 995,000   5,293,000 2,611,000 9,878,000 4,000 3,690,000 3,641,000 563,000 1,643,000 2,587,000 1,218,000 3,421,000 6,029,000 10,000 77,000                               
      supplemental non-cash investing and financing activities:
    		                                                                           
      property and equipment purchased and included in accounts payable
    		 -734,000 1,022,000   396,000 1,222,000    729,000 248,000 -575,000 526,000 253,000 124,000 -91,000 -99,000 218,000 -51,000 62,000 23,000 138,000 244,000 346,000 -37,000 170,000 411,000 -123,000 197,000 36,000 131,000 245,000 31,000 78,000 145,000 57,000 -40,000 85,000                                     
      income taxes payable
    		  7,439,000                                                                         
      principal payments on borrowings under term loan a
    		  -2,031,000                                                                         
      acquired in-process research and development
    		           0        0 0 0 3,753,000     0 0                                               
      loss on extinguishment of debt
    		                                                                           
      gain on sale of andas
    		           0 0                                                               
      changes in operating assets and liabilities, net of acquisitions:
    		                                                                           
      acquisition of novitium pharma llc, net of cash acquired
    		           0 0                                                               
      proceeds from the sale of long-lived assets
    		           0 0                                                               
      proceeds from public offering
    		                                                                           
      principal payments on borrowings under credit agreements
    		   -2,031,000                                                                        
      payment of accrued licensor payment
    		                                                                           
      cash and cash equivalents, beginning of year
    		                                                                           
      cash, cash equivalents and restricted cash, end of year
    		                                                                           
      changes in operating assets and liabilities, net of acquisition:
    		                                                                           
      prepaid income taxes
    		    -3,237,000                                                                       
      cash. cash equivalents, and restricted cash end of period
    		                                                                           
      payments on borrowings under credit agreements
    		     -750,000 -750,000 -750,000 -750,000 -750,000 -750,000 -750,000 -750,000 -750,000 -750,000                                                             
      cash and cash equivalents, end of period
    		     11,513,000 228,597,000     -8,050,000 -7,102,000 -13,525,000 81,911,000 85,046,000 -9,007,000 -811,000 30,073,000 -10,036,000 -9,801,000               11,210,000 1,141,000 -62,733,000 77,747,000 3,771,000 -15,818,000 1,168,000 165,563,000 133,987,000 -17,911,000 175,194                              
      reconciliation of cash, cash equivalents, and restricted cash, beginning of period
    		                                                                           
      cash and cash equivalents
    		     0 221,121,000  0 0 48,228,000 0 0 0 100,300,000 0 0 0 7,864,000 0 0 0 62,332,000  0 0 43,008,000 0 0 0 31,144,000 0 0 0 27,365,000                                         
      restricted cash
    		        0 0 5,006,000 0 0 0 5,001,000 0 0 0 5,003,000 0 0 0 5,029,000 0 0 0 5,021,000 0 0 0 5,006,000 0 0 0 5,002,000                                         
      right-of-use assets obtained in exchange for lease obligations
    		                                                                           
      prepaid expenses and other current assets
    		      1,353,000 -8,379,000 -2,085,000 -64,000 1,513,000 -3,415,000 1,054,000 1,700,000 -137,000 -1,294,000 219,000 823,000 379,000 -2,503,000 -241,000 -150,000 1,028,000 913,000 -1,714,000 846,000 358,000 627,000 -2,875,000 576,000 530,000 1,348,000 -2,201,000 861,000 -25,000 -24,000 1,369,000 -2,193,000 201,000 -312,000 -370,000                                   
      current income taxes payable
    		      3,238,000 7,565,000 4,687,000 -353,000 92,000 -49,000 -1,765,000 -31,000 1,685,000 -637,000 -655,000 -6,034,000 -247,000                        -3,772,000                                 
      changes in operating assets and liabilities, net of acquisition
    		                                                                           
      acquisition of product rights, ipr&d, and other related assets
    		         -4,325,000 -4,000 -4,000 -7,346,000 0 -229,000 -12,000 -12,000 -21,018,000 -39,000 -9,000 -4,048,000 -2,123,000 -56,007,000 329,000 -409,000   0 0                                               
      proceeds from public offering, net of transaction expenses
    		       0                                                                    
      payments on term loan and delayed draw term loan agreements
    		               -2,828,000 -2,828,000 -2,829,000 -2,377,000 -2,377,000 -2,378,000                                                       
      borrowings under prior revolver agreement
    		                                                                           
      repayment of prior credit facility
    		                                                                           
      borrowings under the credit facility, net of issuance costs
    		                                                                           
      proceeds from issuance of convertible preferred stock
    		                                                                           
      net change in cash and cash equivalents
    		           -8,050,000 -7,102,000 -13,525,000 -23,390,000 85,046,000 -9,007,000 -811,000 17,206,000 -10,036,000 -9,801,000                                                       
      cash and cash equivalents, end of year
    		                                                                           
      cash, cash equivalents, and restricted cash, end of period
    		        31,371,000 93,950,000 67,757,000 -8,050,000 -7,102,000 -13,525,000 81,911,000 85,046,000 -9,007,000 -811,000 30,073,000 -10,036,000 -9,801,000 7,288,000 25,416,000 2,663,000 19,091,000 2,366,000 43,241,000 -1,121,000 -10,851,000 3,029,000 56,972,000 13,115,000 9,664,000 -2,456,000 15,827,000                                         
      reconciliation of cash, cash equivalents, and restricted cash, end of period
    		                                                                           
      ​
    		                                                                           
      adjustments to reconcile net income to net cash (used in)/provided by operating activities:
    		                                                                           
      net cash (used in)/provided by operating activities
    		           -4,400,000 3,623,000 -11,484,000 -18,942,000                                                             
      payments on revolver agreement
    		                   0 0                                                       
      borrowings under the credit facility
    		                                                                           
      proceeds from issuance of common stock in public offering
    		                                                                           
      cash paid for costs of share issuances
    		                                                                           
      payments of debt issuance costs
    		               -13,706,000 -121,000                                                           
      net cash (used in)/provided by financing activities
    		           -508,000 -911,000      -2,725,000                 518,000 1,146,000 -38,000 -2,355,000                                     
      cash and cash equivalents, beginning of period
    		           0 0 0 105,301,000 0 0 0 12,867,000 0 0               0 0 0 154,684,000 0 0 0 169,037,000 0 0 -28                              
      fair value of contingent consideration in a business combination
    		                                                                           
      fair value of equity issued as consideration in a business combination
    		                                                                           
      acquisition of product rights included in accounts payable
    		           0                                                                
      debt issuance costs in accrued expenses
    		                 -34,000 115,000                                                         
      net (loss)/income
    		              -20,130,000     -3,635,000 434,000 -12,336,000 -7,011,000                                                     
      adjustments to reconcile net (loss)/income to net cash (used in)/provided by operating activities:
    		                                                                           
      net cash from by financing activities
    		              -2,270,000                                                             
      acquisition of product rights, ipr&d, and other related assets included in returned goods reserve and derivatives and other non-current liabilities
    		                   -8,000                                                        
      asset impairment charge
    		                   341,000                                                        
      borrowings under delayed draw term loan agreement
    		                                                                           
      borrowings under revolver agreement
    		               0 0   0 0 0 15,000,000                                                     
      convertible preferred stock dividends paid
    		                                                                           
      repayment of convertible notes
    		                                                                           
      net cash provided by/(used in) by financing activities
    		                                                                           
      net income/
    		                  86,000                                                         
      adjustments to reconcile net income/(loss) to net cash from operating activities:
    		                                                                           
      acquisition of product rights, ipr&d, and other related assets included in returned goods reserve and accrued liabilities
    		                  388,000                                                         
      loss on repurchase of convertible notes
    		                                                                           
      current income taxes
    		                   5,527,000 -9,907,000 -6,937,000 16,299,000 -262,000 2,628,000 -6,895,000 -1,569,000 4,704,000 2,052,000 -1,672,000 1,100,000 890,000 1,939,000 -7,647,000 1,258,000 3,327,000 -779,000 1,000,000 -23,000 -155,000 50,000                                   
      acquisition of wellspring pharma services inc., net of cash acquired
    		                                                                           
      payment of debt issuance and convertible debt repurchase costs
    		                                                                           
      unwinding of portion of call option overlay
    		                                                                           
      non-cash interest relating to convertible notes and loan cost amortization
    		                     523,000 182,000 1,345,000 1,913,000 1,893,000 1,873,000 2,073,000 2,155,000 2,130,000 2,107,000 1,943,000 1,933,000 1,908,000 1,882,000 1,860,000 1,939,000 1,757,000 1,725,000 1,696,000 1,747,000 1,705,000 1,683,000                                 
      payments on term loan agreement
    		                      -902,000 -902,000 -903,000 0 -902,000 -938,000 -937,000 0 -938,000                                             
      proceeds from stock option exercises
    		                      281,000  133,000 2,303,000 2,416,000 161,000 206,000 1,100,000 1,511,000 162,000 60,000 106,000 25,000 208,000 858,000 360,000 144,000 161,000 414,000 235,000 9,000 42,000 34,000                               
      change in cash, cash equivalents, and restricted cash
    		                      -41,945,000  19,091,000 2,366,000 -4,788,000  -10,851,000 3,029,000 20,822,000  9,664,000 -2,456,000 -16,540,000                                         
      acquisition of product rights, ipr&d, and other related assets included in accounts payable or accrued expenses
    		                      1,940,000                                                     
      intangible asset impairment charge
    		                                                                           
      borrowings under term loan agreement
    		                                                                           
      treasury stock purchases for restricted stock vestings
    		                       0 0 -723,000 -308,000 0 0 -409,000 -250,000                                             
      net cash provided/(used in) by financing activities
    		                                                                           
      reconciliation of cash, cash equivalents, and restricted cash, beginning of period cash and cash equivalents
    		                                                                           
      reconciliation of cash, cash equivalents, and restricted cash, end of period cash and cash equivalents
    		                                                                           
      acquisition of marketing and distribution rights included in accounts payable
    		                                                                           
      acquired product rights and in-process research and development
    		                                                                           
      payment of debt issuance costs
    		                            0 0 -153,000     0 0                                       
      acquisition of product rights and other related assets
    		                          -18,510,000     -46,668,000 0 0 -50,956,000 0 0 -60,312,000 -84,182,000 0 -26,000,000 0 -4,500,000 0                                
      acquisiton of wellspring pharma services inc., net of cash acquired
    		                                                                           
      excess tax benefit from share-based compensation awards
    		                                   310,000 288,000 18,000 1,000 126,000 187,000 38,000 9,000 352,000 424,000                               
      repurchase of common stock under the stock repurchase program
    		                                   0 0                                       
      repurchase of convertible notes
    		                                                                           
      accrued royalties related to asset purchase
    		                                   0 0                                       
      accrued compensation and related expenses
    		                            702,000 -85,000 -811,000 297,000 782,000 92,000 -496,000 205,000 355,000 349,000 -466,000 169,000 175,000 331,000 -835,000                                 
      accrued expenses and other
    		                            1,024,000 -749,000 1,069,000 -1,170,000 1,801,000 -1,148,000 1,161,000                                         
      net borrowings under line of credit agreement
    		                                -5,000,000 0 30,000,000                                         
      adjustments to reconcile net (loss)/income to net cash from operating activities:
    		                                                                           
      net cash provided by/(used in) financing activities
    		                               47,425,000 -4,940,000 -153,000 30,025,000         123,584,000 458,000                               
      treasury stock purchases for restricted stock vestings and forfeitures
    		                                0   0 0                                       
      adjustments to reconcile net income to net cash
    		                                                                           
      provided by operating activities:
    		                                                                           
      changes in restricted cash
    		                                   -1,000 0                                       
      net proceeds from equity offering
    		                                           0 0                               
      net proceeds from convertible debt offering
    		                                                                           
      purchase of call option overlay
    		                                                                           
      proceeds from warrant exercise
    		                                                                           
      change in cash and cash equivalents
    		                                   11,210,000 1,141,000 -62,733,000 -76,937,000 3,771,000 -15,818,000 1,168,000 -3,474,000 133,987,000 -17,911,000 175,222                              
      accrued medicaid rebates
    		                                    -58,000 3,085,000 -1,207,000 203,000 2,537,000 -186,000 -187,000                                 
      accrued expenses, returned goods reserve, and other
    		                                    786,000 -636,000 3,955,000  1,245,000 -825,000 1,000,000                                 
      cash paid for interest
    		                                    0   2,157,000 0     388           0                   
      repurchase of common stock
    		                                      -2,500,000                                     
      accrued royalties assumed in asset purchase
    		                                      1,199,000                                     
      adjustments to reconcile net income to net cash provided by/(used in) operating activities:
    		                                                                           
      loss on disposal of property and equipment
    		                                       0                                    
      non-cash compensation relating to business combination
    		                                             -524                              
      changes in operating assets and liabilities, net of those acquired in business combination:
    		                                                                           
      accrued expenses, returned goods reserve and other
    		                                                                           
      net cash provided by/(used in) continuing operations
    		                                           10,741,000                                
      net cash from discontinued operation
    		                                             -106,184                              
      net cash provided by/(used in) operating activities
    		                                           10,741,000 4,159,000                               
      cash acquired in business combination
    		                                             558                              
      release of restricted cash
    		                                                                           
      net cash (used in)/provided by investing activities
    		                                           -338,000 -22,528,000                               
      repayment of line of credit
    		                                                                           
      treasury stock purchases
    		                                             -438                              
      issuance of common stock in connection with business combination
    		                                                                           
      cancellation of series d, series c, series b, and series a preferred stock
    		                                                                           
      acquired non-cash net assets
    		                                                                           
      preferred stock dividends accrued
    		                                                                           
      contingent payable for asset purchase
    		                                                                           
      property and equipment purchased on credit
    		                                        59,000 -55,000 105,000                                 
      prepaid expenses
    		                                          437,000 -539,000 -106,000 143                              
      non-cash interest relating to equity-linked securities and loan cost amortization
    		                                                                           
      accrued expenses, returned goods reserve and deferred revenue
    		                                            2,989,000 407,858                              
      borrowings under line of credit
    		                                                                           
      proceeds from warrant exercises
    		                                            0                               
      acquisition of intangible assets
    		                                                                           
      cash (received)/paid for interest
    		                                                                           
      accrued compensation
    		                                                                           
      net cash from continuing operations
    		                                             -791,131                              
      net cash provided by/(used in) investing activities
    		                                             2,230,973                              
      (repayments)/borrowings under line of credit
    		                                             307                              
      net cash (used in)/provided by continuing operations
    		                                             -1,158,436                              
      issuance of common and preferred stock upon cashless warrant exercise
    		                                                                           
      issuance of preferred stock upon convertible debt conversion
    		                                                                           
      net income from continuing operations
    		                                                                           
      used in operating activities:
    		                                                                           
      non-cash interest relating to convertible debt and loan cost amortization
    		                                                                           
      acquisition of property and equipment, net of disposals
    		                                                                           
      issuance of common stock in business combination
    		                                                                           
      cancellation of series d, series c, series b, series a, and common stock
    		                                                                           
      acquired intangibles
    		                                                                           
      acquired goodwill
    		                                                                           
      acquired restricted cash
    		                                                                           
      other acquired tangible assets
    		                                                                           
      assumed liabilities
    		                                                                           
      preferred stock dividends
    		                                                                           
      cash flows (used in) operating activities
    		                                                                           
      adjustments to reconcile net income to net cash (used in) operating activities
    		                                                                           
      loss on disposal of fixed assets
    		                                                117,362 0 432   0 2,099                     
      gain on sale of intellectual property
    		                                                                           
      employee and director stock-based compensation
    		                                              145,794    313,027    300,385                     
      convertible note fair value adjustment
    		                                              285,329 290,671 843,412 -15,953 3,210,338 -1,905,573 -463,000 1,753,000 639,000                     
      changes in other assets and liabilities affecting cash flows from operations
    		                                                                           
      accounts payable and accrued liabilities
    		                                                   -2,858,956 -190,360 -1,227,452 4,410,871 -40,967 404,879 477,124 2,301,042 -1,675,443    -615,621 694,770 701,068 1,409,626 2,051,657 -228,943 324,297 -1,697,155     
      net cash (used in) operating activities
    		                                                                           
      cash flows (used in) investing activities
    		                                                                           
      funding of restricted cash
    		                                                                           
      proceeds from sale of intellectual property
    		                                              1,000,000                             
      purchase of fixed assets
    		                                                                           
      purchase of investment
    		                                                                           
      net cash (used in) investing activities
    		                                                                           
      net (decrease) in cash and cash equivalents
    		                                                                           
      cash and cash equivalents at beginning of period
    		                                              34,794,341 0 0 0 57,225,234 0 0 0 38,155,251 0 0 0 29,858,465 0 0 0 11,760,920 0            
      cash and cash equivalents at end of period
    		                                              29,388,772 -3,254,754 -4,367,950 -7,056,687 49,473,732 -12,374,965 32,474,193 -14,223,015 51,349,021 2,629,234 -10,856,095 5,219,111 41,163,001 16,689,207 7,183,435 -4,176,523 10,162,346 6,060,222 -4,624,880 -2,780,546 13,106,123 -9,753,615 -1,979,604 16,091,426 11,290,742 7,287,678 232,569 63,416 70,189 
      supplemental schedule of cash flow information
    		                                                                           
      noncash financing activities
    		                                                                           
      shares issued for convertible senior notes and accrued interest
    		                                               0 3,748,518 0 10,132,534                         
      cash flows used in operating activities
    		                                                                           
      stock warrant expense - noncash
    		                                                   24,221 28,205 102,144 50,410 8,334 0 19,759 37,436  3,209 19,868 11,657 -9,366 50,037 28,649 34,964         
      loss on disposal or impairment of equipment
    		                                                                           
      investment impairment charge
    		                                                                           
      other non-cash items
    		                                                                           
      changes in assets and liabilities affecting cash flows from operations
    		                                                                           
      cash flows used in investing activities
    		                                                                           
      purchase of investments
    		                                                                           
      proceeds from sale of fixed assets
    		                                                       825                    
      fractional share payout
    		                                                                           
      cash paid for convertible note repayment
    		                                                                           
      proceeds from common stock option exercises
    		                                                                           
      proceeds from common stock warrant exercises
    		                                                                           
      proceeds from issuance of common stock by underwritten offering
    		                                                                           
      proceeds from issuance of common stock by registered direct offering
    		                                                                           
      net increase in cash and cash equivalents
    		                                                                 -2,780,546 -2,542,825 -9,753,615 -1,979,604 16,091,426 3,636,890 7,287,678    
      interest paid, including acquired accrued interest
    		                                                                           
      noncash investing and financing activities:
    		                                                                           
      investment - non-cash
    		                                                                           
      purchase of fixed assets on account, non-cash investing activity
    		                                                   -37,611 20,630                       
      adjustments to reconcile net income to net cash (used in) operations
    		                                                                           
      employee & director stock-based compensation
    		                                                270,002    305,162    268,154 278,665 204,971  305,199 305,199 336,119  305,188 301,111 258,775         
      prepaid expenses, deposits and other assets
    		                                                37,308    69,605    -212,610                   
      proceeds from warrants exercised
    		                                                                           
      proceeds from issuance of common stock by underwritten public offering
    		                                                                           
      proceeds from issuance of common stock by registered direct offerings
    		                                                    17,415 -29,672 23,888,627                     
      interest paid
    		                                                0    0                       
      noncash investing and financing activities
    		                                                                           
      unpaid costs associated with registered direct offering
    		                                                                           
      unpaid costs associated with underwritten public offering
    		                                                                           
      net (decrease) cash and cash equivalents
    		                                                                           
      net (decrease)/increase cash and cash equivalents
    		                                                                           
      excess consideration paid over fair value
    		                                                                           
      loss on disposal of equipment
    		                                                                   0 -2,450       
      redemption of short term investments
    		                                                           -11,648 0 0 3,037,982 8,878,288 1,101,354   -1 0   6,094,908 2,324,216 2,683,141 1,902,458 
      cash paid for transaction related costs
    		                                                                           
      cash received in transaction
    		                                                                           
      liabilities acquired through cell genesys transaction
    		                                                                           
      shares issued for cell genesys transaction
    		                                                                           
      investment aquired through cell genesys transaction
    		                                                                           
      other assets acquired in cell genesys transaction
    		                                                                           
      loss on write-down of fixed assets
    		                                                                           
      investment impairment loss - noncash
    		                                                                           
      proceeds from common stock option exercised
    		                                                                           
      net increase cash and cash equivalents
    		                                                      13,193,770  -10,856,095 5,219,111 11,304,536                 
      deferred revenue
    		                                                                 -4,545 -4,546 -9,091 -9,091 -6,818 -34,091     
      credit equity financing facility
    		                                                                           
      mark-to-market of convertible senior notes
    		                                                        -103,000 381,916 1,409,000                 
      acquisition related costs
    		                                                                           
      other noncash charges
    		                                                                           
      gain on disposal of fixed assets
    		                                                                           
      changes in other assets and liabilities affecting cash flows from operations:
    		                                                                           
      due to licensor - antares
    		                                                            -8,329   730 -309 -1,960 5,869         
      purchase of short term investments
    		                                                                 -15,991 -68,074 -11,053,342 -49,104 -47,545 -60,988     
      purchase of capital assets
    		                                                                 -114,091 -14,625         
      cash paid for acquisition related costs
    		                                                                           
      proceeds from sale or conversion of shares
    		                                                        -264 14,115,849 17,473,307 12,134    -60,343 345,750     18,184,443 142,662 -1 7,146,937 -6,323 243,675 
      supplementary information
    		                                                                           
      other information:
    		                                                                           
      accrued liabilities for acquisition related costs, noncash
    		                                                                           
      accrued liabilities for deferred acquisition costs, noncash
    		                                                                           
      adjustments to reconcile net income to net cash from operating activities
    		                                                                           
      stock warrant expense — noncash
    		                                                                           
      other non-cash charges
    		                                                                           
      fair value adjustment
    		                                                                           
      matc license revenue — noncash
    		                                                                           
      benefit from contingencies
    		                                                                      -137,647     
      due to licensor — antares
    		                                                                           
      purchase of capital assets on account, non-cash investing activity
    		                                                               -102,421            
      investment in matc — noncash
    		                                                                           
      impairment of short term investments
    		                                                                0           
      (gain) on disposal of equipment
    		                                                                           
      unrealized gain on available-for-sale securities, non-cash
    		                                                                           
      cash flows (used in) financing activities
    		                                                                           
      net cash (used in) financing activities
    		                                                                           
      unrealized loss on available-for-sale securities, noncash
    		                                                                  602,000         
      matc license revenue - noncash
    		                                                                           
      investment in matc - noncash
    		                                                                           
      (gain) loss on disposal of equipment
    		                                                                           
      income tax paid
    		                                                                    0 0 75,000     
      adjustments to reconcile net income to
    		                                                                           
      changes in other assets and liabilities
    		                                                                           
      affecting cash flows from operations
    		                                                                           
      at beginning of period
    		                                                                 0 15,648,948  0 0 7,653,852  0 0 310,643 
      see accompanying notes to the condensed financial statements.
    		                                                                           
      stock warrant expense-noncash
    		                                                                           
      matc license revenue-noncash
    		                                                                           
      due to licensor-antares
    		                                                                           
      supplemental schedule of noncash investing cash flow information
    		                                                                           
      investment in matc
    		                                                                           
      employee & director compensation - noncash
    		                                                                    147,341 142,905 220,798 52,407 49,203 116,209 859,013 
      consultant compensation - noncash
    		                                                                           
      prepaid expenses, deposits and other sundry assets
    		                                                                    -200,394    -62,615   
      accrual for contingencies
    		                                                                    -137,647    -201,765 0 140,000 
      purchases of capital assets
    		                                                                    -806       
      proceeds from sale of shares and exercise of options
    		                                                                           
      and warrants
    		                                                                           
      see accompanying notes to the financial statements.
    		                                                                           
      prepaid expenses and other sundry assets
    		                                                                      -8,405    17,500 
      amortization of deferred unearned compensation
    		                                                                           
      repurchase of licensing rights
    		                                                                           
      purchased in-process research and development
    		                                                                           
      due from sbi
    		                                                                           
      issuance of convertible debenture
    		                                                                           
      supplemental schedule of
    		                                                                           
      cash flow information
    		                                                                           
      acquisition of sbi
    		                                                                           
      other net liabilities assumed
    		                                                                           
      less: subordinate voting shares issued therefor
    		                                                                           
      -
    		                                                                           
      significant non-cash transactions
    		                                                                           
      fair value of common stock warrants issued in connection
    		                                                                           
      with the sale of capital stock
    		                                                                           
      accounts payable and accrued expenses
    		                                                                           
      due to licensor
    		                                                                           
      proceeds from sales or conversion of shares
    		                                                                           
      net increase in cash
    		                                                                           
      and cash equivalents
    		                                                                           
      less: common stock issued therefor
    		                                                                           
      due from licensee
    		                                                                           
      fair value of common stock warrants issued in connection with the sale of capital stock
    		                                                                           
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.